Febrile Neutropenia - Pipeline Review, H2 2013 - New Study Released
Global Markets Direct's, 'Febrile Neutropenia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Febrile Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Febrile Neutropenia. Febrile Neutropenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations...
View full press release